Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Monitoring response to immune checkpoint inhibition in patients with endometrial cancer using cell-free DNA analysis
    Meeting Abstract

    Manning-Geist, B.; Patel, J.; Marra, A.; Zammarrelli, W. A. 3rd; Da Cruz Paula, A.; Abu-Rustum, N.; Shah, R.; Berger, M.; Hensley, M.; Lakhman, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Efficacy and safety profile of mirvetuximab in folate receptor alpha-positive ovarian cancer
    Meeting Abstract

    Johannet, P.; Foote, M.; Cohen, S.; Friedman, C.; Green, A.; Guo, R.; Hensley, M.; Konner, J.; Kyi, C.; Liu, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Chen, M. F.; Pagliaro, A.; Ogliari, F. R.; Stockhammer, P.; Aldea, M.; Grant, M.; De Giglio, A.; Alessi, J. V.; Pecci, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save